Company
Headquarters: Lane Cove, NSW, Australia
Employees: 339
CEO: Mr. Michael C. Kavanagh BSc, M.B.A.
A$881.8 Million
AUD as of July 1, 2024
US$587.3 Million
Company | Market Cap (USD) |
---|---|
Intuitive | $154.23 B |
EssilorLuxottica SA | $98.99 B |
Becton, Dickinson and Company | $65.82 B |
Alcon Inc. | $43.72 B |
HOYA Corp | $42.76 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally. The company engages in the manufacturing and distribution of the trophon ultrasound probe disinfector, and its associated consumables and accessories; and research, development, and commercialization of infection control and decontamination products and related technologies. It provides trophon2, an ultrasound probe high level disinfection device; trophon EPR, a low temperature high level disinfection solution for intra-cavity ultrasound probes; and Nanosonics AuditPro, an infection control workflow compliance management solution. The company offers its products primarily to sonographers, hospitals, obstetricians, and gynecologists. Nanosonics Limited was incorporated in 2000 and is headquartered in Lane Cove, Australia.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Nanosonics Limited has the following listings and related stock indices.
Stock: ASX: NAN wb_incandescent